Direct targeted therapy for MLL‐fusion‐driven high‐risk acute leukaemias

Direct targeted therapy for MLL‐fusion‐driven high‐risk acute leukaemias

Abstract Background Improving the poor prognosis of infant leukaemias remains an unmet clinical need. This disease is a prototypical fusion oncoprotein‐driven paediatric cancer, with MLL (KMT2A)‐fusions present in most cases. Direct targeting of these driving oncoproteins represents a unique therape...

Full description

Bibliographic Details
Main Authors: Sandra Cantilena, Luca Gasparoli, Deepali Pal, Olaf Heidenreich, Jan‐Henning Klusmann, Joost H. A. Martens, Alexandre Faille, Alan J. Warren, Mawar Karsa, Ruby Pandher, Klaartje Somers, Owen Williams, Jasper de Boer
Format: Article
Language:English
Published: Wiley 2022-06-01
Series:Clinical and Translational Medicine
Subjects:
leukaemia
MLL‐fusion
mouse models
precision medicine
targeted therapy
Online Access:https://doi.org/10.1002/ctm2.933

Internet

https://doi.org/10.1002/ctm2.933

Similar Items